Verisante Technology has secured a Health Canada licence for Verisante Aura, a non-invasive optical system designed to detect of skin cancers early.

The optical system uses Raman spectroscopy to automate the current process of diagnosis, allowing for the rapid scanning of skin lesions.

The device can detect melanomas, basal cell skin cancers and squamous cell skin cancers.

Verisante president and CEO Thomas Braun said that Verisante Aura will help healthcare professionals to assess skin lesions, reduce patient waiting times and lower costs by detecting skin cancer at an early and most easily treatable stage.

Verisante will now have to pay a milestone payment of $120,000 to BC Cancer Agency, having obtained the Health Canada Licence.

The company intends to receive additional regulatory approvals in the EU and Australia by the end of 2011, after which it will pursue US Food and Drug Administration approval.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.